ACM Research Inc
For the period ended Jun 30, 2024. Filed Aug 7, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2024 · Filed Aug 7, 2024
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 5. Other Information
On May 14, 2024, David Wang, President, Chief Executive Officer and a member of the Board of Directors of ACM Research, adopted a Rule 10b5-1 trading arrangement (the “Wang Plan”) that is intended to satisfy the affirmative defense of Rule 10b5-1(c) of the Exchange Act. The Wang Plan allows for the contemporaneous exercise of options and sale of up to 480,000 shares of Class A Common Stock, at specific market prices, commencing on August 22, 2024, and continuing until (i) all such options are exercised and the underlying shares are sold, (ii)April 30, 2025, or (iii) such date that the Wang Plan is otherwise terminated according to its terms, whichever comes first.
On May 17, 2024, Tracy Liu, amember of the Board of Directors of ACM Research, adopted a Rule 10b5-1 trading arrangement (the “Liu Plan”) that is intended to satisfy the affirmative defense of Rule 10b5-1(c) of the Exchange Act. The Liu Plan allows for the contemporaneous exercise of options and sale of up to 19,500 shares of Class A Common Stock, at specific market prices, commencing on August 16, 2024, and continuing until (i) all such options are exercised and the underlying shares are sold, (ii)May 19, 2025, or (iii) such date that the Liu Plan is otherwise terminated according to its terms, whichever comes first.
On May 31, 2024, Fuping Chen, Vice President, Sales—China of ACM Shanghai, adopted a Rule 10b5-1 trading arrangement (the “Chen Plan”) that is intended to satisfy the affirmative defense of Rule 10b5-1(c) of the Exchange Act. The Chen Plan allows for the contemporaneous exercise of options and sale of up to 100,000 shares of Class A Common Stock, at specific market prices, commencing on August 30, 2024, and continuing until (i) all such options are exercised and the underlying shares are sold, (ii)May 30, 2025, or (iii) such date that the Chen Plan is otherwise terminated according to its terms, whichever comes first.
On June 12, 2024, Shanghai Science and Technology Venture Capital Co., Ltd. ("SSTVC"), adopted a Rule 10b5-1 trading arrangement (the “SSTVC Plan”) that is intended to satisfy the affirmative defense of Rule 10b5-1(c) of the Exchange Act. The SSTVC Plan allows for the sale of up to 1.1 million shares of Class A Common Stock, at specific market prices, commencing on September 10, 2024, and continuing until (i) all such shares are sold, (ii)December 31, 2024, or (iii) such date that the SSTVC Plan is otherwise terminated according to its terms, whichever comes first. Xia Xing, a member of the Board of Directors of ACM Research, is an employee of an affiliate of SSTVC.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.